Home > Services > Neutralized Antibody Drug Discovery
   Neutralized Antibody Drug Discovery

The Covid-19 pandemic has demonstrated the importance of rapidly developing neutralizing antibody against those dangerous microbes that are easily transmitted, virulent and invasive to central organs such as lung. The infection often induces strong immune reactions in patients. The serum of recovered patients (especially those naturally recovery without medication) often contains high titer neutralizing antibodies against the infectious organism. Identifying the sequence of the neutralizing antibodies from recovered patients provides one of best pathway to quickly develop antibody drugs against the disease. Single cell gene sequencing technique has been used to identifying neutralizing antibodies from patient serum. However, one of the drawbacks of this approach is that the sequencing is carried out on B-memory cells from PBMC, while the plasma cells that producing neutralizing antibodies are only present in bone marrow so the single cell sequencing with PBMC will most likely miss the most valuable neutralizing antibody sequences. To address this issue, we have develop a proprietary technology platform to de novo sequencing complex mixture of antibodies from human serum and to identify the real high affinity neutralizing antibody sequences with a native heavy chain and light chain paring.

Process Diagram:

Please contact us for your neutralized antibody development inquiry or request.

Sample Requirement:

Immunoglobulin from ~100-200ml serum of recovered patients by protein A or ProteinG purification and ~1mg antigen in Fc, GST or other fusion format.


Developing neutralizing antibody drugs.

Related Service & Products

  1. Recombinant Antibody Expression